Adbry™ (tralokinumab-ldrm) – New drug approval
On December 28, 2021, Leo Pharma announced the FDA approval of Adbry (tralokinumab-ldrm), for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Top